Vident Investment Advisory’s Dr. Reddy's Laboratories RDY Stock Holding History

Vident Investment Advisory’s Portfolio RDY Stock Details RDY Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q3	–	Sell	-87,315	Closed	-$1.1M	–	803
2023 Q2	$1.1M	Buy	87,315 +9,695	+12%	+$113K	0.04%	456
2023 Q1	$884K	Buy	77,620 +14,375	+23%	+$155K	0.03%	563
2022 Q4	$655K	Buy	+63,245	New	+$682K	0.02%	623
2022 Q3	–	Sell	-18,765	Closed	-$207K	–	1281
2022 Q2	$207K	Buy	+18,765	New	+$204K	0.01%	1128

Other funds holding RDY

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

Royal Bank of Canada Toronto, Ontario, Canada $672B AUM 33.48% 1-Year Est. Return

Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return

Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return

Robeco Institutional Asset Management Rotterdam, Netherlands $81.4B AUM 40.71% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return

Man Group London, United Kingdom $62.7B AUM 29.77% 1-Year Est. Return

Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return

GQG Partners Ft. Lauderdale, Florida $53.8B AUM 19.23% 1-Year Est. Return

Vident Investment Advisory's RDY Position: Q3 2023 in Review

Vident Investment Advisory sold out of Dr. Reddy's Laboratories (RDY) in Q3 2023, closing a stake of 87,315 shares — an estimated $1.1M sold.

Vident Investment Advisory first reported a position in RDY in Q2 2022 and held it in 4 quarters. The position peaked at $1.1M in Q2 2023. 212 funds tracked by Wall St. Rank hold RDY as of Q3 2023.

Vident Investment Advisory reported no remaining Dr. Reddy's Laboratories position as of Q3 2023 after selling out during the quarter.
Vident Investment Advisory sold 87,315 Dr. Reddy's Laboratories shares in Q3 2023, an estimated $1.1M.
Vident Investment Advisory first reported a position in Dr. Reddy's Laboratories in Q2 2022 and held it in 4 quarters.
Vident Investment Advisory's Dr. Reddy's Laboratories position peaked at $1.1M in Q2 2023.
212 funds tracked by Wall St. Rank held Dr. Reddy's Laboratories as of Q3 2023.

Based on Vident Investment Advisory's 13F filing for Q3 2023.